Prostanoid receptor EP1 expression in breast cancer

Modern Pathology

Volumn 21, Issue 1, 2008, Pages 15-21

  Thorat, Mangesh A ^a   Morimiya, Akira ^a   Mehrotra, Sanjana ^a   Konger, Raymond ^a   Badve, Sunil S ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Breast cancer; Cyclooxygenase; EP1 receptor; Immunohistochemistry; PGE2; Prostanoid receptor

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR; PROSTANOID RECEPTOR EP1; PROSTANOID RECEPTOR EP2; PROSTANOID RECEPTOR EP3; PROSTANOID RECEPTOR EP4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECOND MESSENGER; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, PROSTAGLANDIN E; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 37549004432     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800970     Document Type: Article

References (26)

1. CDC. (cited 15 January 2007). Available from:http://www.cdc.gov/cancer/ breast/statistics/.
2. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer 2002;9:15-32.
3. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999;6:71-73.
4. Leris C, Mokbel K. The prevention of breast cancer: an overview. Curr Med Res Opin 2001;16:252-257.
5. Nakatsugi S, Ohta T, Kawamori T, et al. Chemo-prevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6- phenylimidazo[ 4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000;91:886-892.
6. Egan KM, Stampfer MJ, Giovannucci E, et al. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-993.
7. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-1250.
8. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
9. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
10. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
11. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
12. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in nonsmall cell lung cancer. Clin Cancer Res 2001;7:2669-2674.
13. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-3976.
14. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
15. Chell S, Kadi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006;1766:104-119.
16. Kawamori T, Uchiya N, Nakatsugi S, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001;22:2001-2004.
17. Watanabe K, Kawamori T, Nakatsugi S, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999;59:5093-5096.
18. Zhao Y, Agarwal VR, Mendelson CR, et al. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-5742.
19. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987.
20. Breyer RM, Kennedy CR, Zhang Y, et al. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann N Y Acad Sci 2000;905:221-231.
21. Konger RL, Billings SD, Thompson AB, et al. Immunolocalization of low-affinity prostaglandin E receptors, EP and EP, in adult human epidermis. J Invest Dermatol 2005;124:965-970.
22. Lord JT, Ziboh VA. Specific binding of prostaglandin E2 to membrane preparations from human skin: receptor modulation by UVB-irradiation and chemical agents. J Invest Dermatol 1979;73:373-377.
23. Morita I, Schindler M, Regier MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995;270:10902-10908.
24. Otto JC, Smith WL. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J Biol Chem 1994;269:19868-19875.
25. Lee JL, Kim A, Kopelovich L, et al. Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 2005;125:818-825.
26. Zhao Y, Agarwal VR, Mendelson CR, et al. Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 1997;61:203-210.